Astrazeneca (NYSE:AZN) Posts Quarterly Earnings Results, Beats Estimates By $0.13 EPS

Astrazeneca (NYSE:AZN) released its quarterly earnings results on Monday. The company reported $2.63 earnings per share for the quarter, topping analysts’ consensus estimates of $2.50 by $0.13, FiscalAI reports. The business had revenue of $15.38 billion during the quarter, compared to the consensus estimate of $15.44 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. The business’s quarterly revenue was up 6.4% compared to the same quarter last year. During the same quarter last year, the company earned $2.17 earnings per share.

Here are the key takeaways from Astrazeneca’s conference call:

• First-half revenue rose 6% and core EPS increased 11%; excluding generic-pressured Farxiga and Brilinta, revenue grew 11%. AstraZeneca reiterated its full-year outlook for mid-to-high single-digit revenue growth and low-double-digit core EPS growth.
• The pipeline delivered six positive Phase III readouts and more than 20 major-market approvals, including launches of BAXFENDY and camizestrant. The company highlighted 25 planned Phase III readouts over the next 18 months and remains confident in its $80 billion 2030 revenue ambition.
• Oncology remained a major growth engine, with revenue up 15% in the first half; Enhertu, Imfinzi/Imjudo, Calquence, Truqap and Datroway all posted strong quarterly growth. Positive VOLGA bladder-cancer data and sonesitatug vedotin’s overall-survival benefit in CLDN18.2-positive gastric cancer could support additional long-term growth.
• BioPharmaceuticals revenue declined 5% as Farxiga, Brilinta and roxadustat faced loss-of-exclusivity and pricing pressure; Farxiga revenue fell 90% in the quarter after U.S. generic entry. The CARDIO-TTRansform trial for Wainua also failed to show a statistically significant benefit on its primary composite endpoint.
• AstraZeneca is accelerating investment in future growth, including Phase III programs for oral GLP-1 candidate elecoglipron and preparations for tozorakimab in COPD. Management said tozorakimab’s positive results increased its peak-sales expectation to more than $5 billion, while sonesitatug vedotin is now estimated at $3 billion–$5 billion.

Astrazeneca Stock Up 0.4%

Shares of NYSE:AZN opened at $170.02 on Tuesday. The company’s fifty day moving average is $180.27 and its two-hundred day moving average is $187.99. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91. Astrazeneca has a 1-year low of $142.98 and a 1-year high of $212.71. The stock has a market capitalization of $263.68 billion, a price-to-earnings ratio of 25.53, a price-to-earnings-growth ratio of 1.38 and a beta of 0.24.

Institutional Investors Weigh In On Astrazeneca

Several institutional investors and hedge funds have recently bought and sold shares of the business. Citigroup Inc. boosted its position in Astrazeneca by 65.3% during the 4th quarter. Citigroup Inc. now owns 6,154,760 shares of the company’s stock valued at $1,080,160,000 after purchasing an additional 2,431,890 shares during the period. Raymond James Financial Inc. lifted its stake in Astrazeneca by 64.8% in the second quarter. Raymond James Financial Inc. now owns 3,783,251 shares of the company’s stock valued at $264,373,000 after buying an additional 1,487,662 shares during the last quarter. Alyeska Investment Group L.P. lifted its stake in Astrazeneca by 218.5% in the fourth quarter. Alyeska Investment Group L.P. now owns 1,726,795 shares of the company’s stock valued at $303,053,000 after buying an additional 1,184,630 shares during the last quarter. Mackenzie Financial Corp boosted its holdings in shares of Astrazeneca by 161.0% during the fourth quarter. Mackenzie Financial Corp now owns 1,484,312 shares of the company’s stock valued at $260,497,000 after acquiring an additional 915,711 shares during the period. Finally, National Bank of Canada FI boosted its holdings in shares of Astrazeneca by 328.9% during the third quarter. National Bank of Canada FI now owns 1,119,192 shares of the company’s stock valued at $85,869,000 after acquiring an additional 858,263 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

Astrazeneca News Roundup

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: Quarterly earnings beat expectations: AstraZeneca reported adjusted earnings of $2.63 per share, above the $2.50 consensus estimate. Second-quarter revenue increased 6.4% year over year to $15.38 billion, narrowly missing the $15.44 billion forecast. Management reiterated its 2026 guidance, which helped reassure investors about near-term performance. AstraZeneca beats second-quarter profit expectations, holds outlook
• Positive Sentiment: Growth is concentrated in key franchises: Oncology and rare-disease medicines generated robust demand, while cardiovascular products also supported results. These businesses helped counter generic pressure affecting several established drugs and reinforced AstraZeneca’s ability to deliver growth despite product exclusivity challenges. AZN Q2 Earnings and Sales Beat, Key Drugs Offset Generic Pressure
• Neutral Sentiment: Long-term revenue ambition remains intact: AstraZeneca continues to target approximately $80 billion in revenue, arguing that its broader pipeline can offset individual clinical setbacks. The outlook supports investor confidence, but achieving the ambition will depend on successful launches and continued execution. Pipeline speed bump doesn’t shake AstraZeneca’s $80 billion revenue ambition
• Negative Sentiment: Ultomiris trial failure raises pipeline concerns: The rare-disease drug failed to meet the main goal in a late-stage study involving a blood-vessel complication after stem-cell transplantation. The result adds to recent development setbacks and could increase scrutiny of AstraZeneca’s longer-term growth prospects. AstraZeneca’s rare disease drug misses main goal in late-stage trial
• Negative Sentiment: U.S. pricing policy may pressure future economics: An executive said AstraZeneca is adjusting pricing strategies for new launches in response to the Trump administration’s most-favoured-nation drug-pricing policy. Potentially lower U.S. prices could limit revenue or margins, even as the company seeks to protect access and launch prospects. AstraZeneca drug prices evolving in response to Trump policy

Wall Street Analysts Forecast Growth

AZN has been the topic of a number of research analyst reports. Bank of America reiterated a “buy” rating on shares of Astrazeneca in a research note on Wednesday, July 1st. The Goldman Sachs Group restated a “buy” rating on shares of Astrazeneca in a research note on Wednesday, July 1st. Jefferies Financial Group reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Friday, June 26th. Wall Street Zen upgraded Astrazeneca from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Finally, JPMorgan Chase & Co. reissued a “buy” rating on shares of Astrazeneca in a report on Tuesday, June 30th. Thirteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $211.00.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.